Paul M. Kinsella

Partner

kinsella-paul-m
  • JD, with distinction, Stanford Law School, 1993
  • BA, summa cum laude, Boston College, 1988

Qualifications

  • Massachusetts, 1995
  • California, 1993
  • North Carolina, 2017
  • The Legal 500 (2014-2017)
  • Chambers USA: America's Leading Lawyers for Business (2011-2017)
  • The Best Lawyers in America (2006-2012, 2015-2018)
  • Massachusetts Super Lawyers (2014-2016)

Paul M. Kinsella

Partner

Paul represents public corporations in business combinations, securities offerings, and governance matters.

Experience

Examples of client relationships include advising:

  • Cubist on sale to Merck ($9.5 billion); acquisitions of Trius, Optimer, and Adolor; convertible note offerings; and securities and governance matters.
  • Genzyme on sale to Sanofi ($20.1 billion); acquisitions of Bioenvision, AnorMED, Bone Care, ILEX ($1.1 billion), SangStat, Focal, GelTex ($1.3 billion), and Biomatrix; proxy contest with entities affiliated with Carl Icahn; cooperation agreement with Relational Investors; convertible and straight debt offerings; accelerated share repurchase program; divestitures of genetics business unit, diagnostics business unit, cardiothoracic devices business, and Snowden-Pencer line of surgical instruments; and securities and governance matters.
  • Medtronic/Covidien on acquisitions of HeartWare ($1.1 billion), ev3 ($2.6 billion), Maya Medical, VNUS Medical, Power Medical Interventions, Aspect Medical, and Twelve.
  • NxStage in pending sale to Fresenius Medical Care Holdings ($2 billion).
  • Pfizer/Wyeth on acquisitions of Medivation ($14 billion), Hospira ($17 billion), Icagen, Excaliard, and Scion; sale of Primatene Mist; and securities law matters.
  • Shire on acquisitions of Baxalta ($32 billion) and Dyax ($5.9 billion).
  • Synageva on sale to Alexion ($8.9 billion) and multiple common stock offerings.
  • Wright Medical on merger of equals with Tornier ($3.3 billion), which resulted in parent company domiciled in the Netherlands; convertible note offerings; acquisition of Solana Surgical; and securities and governance matters.